Treatment of opioid‐induced constipation with oral naloxone: A pilot study Journal Article


Authors: Culpepper‐Morgan, J. A.; Inturrisi, C. E.; Portenoy, R. K.; Foley, K.; Houde, R. W.; Marsh, F.; Kreek, M. J.
Article Title: Treatment of opioid‐induced constipation with oral naloxone: A pilot study
Abstract: Opioids cause constipation by binding to specific opioid receptors in the enteric and central nervous systems. First‐pass glucuronidation limits systemic bioavailability of oral naloxone. This study was designed to determine if oral naloxone could reverse opioid‐induced constipation without precipitating abstinence or recrudescence of pain in opioid‐dependent individuals. Concentrations of unmetabolized and total naloxone, including naloxone glucuronide, were measured by radioimmunoassay. A dose‐related increase in symptoms of laxation resulted in all three opioid‐dependent patients studied that paralleled the increase in active and total naloxone plasma levels. Withdrawal symptoms occurred with plasma naloxone area under the plasma concentration—time curves above 550 ng · min/ml and with dosing intervals less than 3 hours. Peak plasma levels did not predict withdrawal. Oral naloxone ameliorates opioid‐induced constipation in opioid‐dependent persons. Titration of dose to a maximum of 12 mg at least 6 hours apart may be needed to avoid adverse reactions. Clinical Pharmacology and Therapeutics (1992) 52, 90–95; doi: © 1992 American Society for Clinical Pharmacology and Therapeutics
Keywords: adult; unclassified drug; constipation; case report; pain; opiate; withdrawal syndrome; dose-response relationship, drug; pilot projects; paracetamol; methadone; substance-related disorders; metoclopramide; naloxone; oxycodone; opiate addiction; oral drug administration; middle age; docusate sodium; laxative; bisacodyl; sodium dihydrogen phosphate; human; male; female; priority journal; article; bile salt; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; senna; bilron; castor oil; fleet enema
Journal Title: Clinical Pharmacology & Therapeutics
Volume: 52
Issue: 1
ISSN: 0009-9236
Publisher: Nature Publishing Group  
Date Published: 1992-07-01
Start Page: 90
End Page: 95
Language: English
DOI: 10.1038/clpt.1992.106
PUBMED: 1623695
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 30 July 2019 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Kathleen M Foley
    200 Foley
  2. Raymond   Houde
    26 Houde
  3. Russell K. Portenoy
    165 Portenoy